

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/552,177	
			Filing Date	October 5, 2005	
			First Named Inventor	Ahearn, Joseph M.	
			Art Unit	1641	
			Examiner Name	Unassigned	
Sheet	1	of	3	Attorney Docket Number	021182-000410US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/GG/	AA	US-2005/0037441 A1	02-17-2005	Ahearn et al.	.....
/GG/	AB	US-2005/0042602 A1	02-24-2005	Ahearn et al.	.....
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
/GG/	AS	WO	03/022223 A2		20-03-2003	Univ. of Pittsburg	.....	<input type="checkbox"/>
/GG/	AT	WO	94/10571 A1		05-11-1994	T Cell Sciences Inc.	.....	<input type="checkbox"/>
	AU							<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>

Examiner Signature	/Gailene Gabel/ (12/04/2008)	Date Considered	12/04/2008
--------------------	------------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60735202 v1

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/552,,177
				Filing Date	October 5, 2005
				First Named Inventor	Ahearn, Joseph M.
				Art Unit	1641
Examiner Name	Unassigned				
Attorney Docket Number	021182-000410US				
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/GG/	AX	ALEXANDER, Elaine, et al., " <u>Serum complement activation in central nervous system disease in sjogren's syndrome</u> ," The American Journal of Medicine, October 1988, Vol. 85, No. 4, abstract only.	<input type="checkbox"/>	
	AY	ATKINSON, J.P., et al., " <u>Origin of the Fourth Component of Complement Related Chido and Rodgers Blood Group Antigens</u> ," 1988; Complement; Vol. 5; pp. 65-76	<input type="checkbox"/>	
	AZ	BOMBARDIER, Claire, et al., " <u>Derivation of the SLEDAI A Disease Activity Index for Lupus Patients</u> ," Arthritis Rheum, June 1992, Vol. 35; No. 6; pp. 630-640.	<input type="checkbox"/>	
	AAA	CHUDWIN, D., et al., " <u>Activation of the Alternative Complement Pathway by Red Blood Cells from Patients with Sickle Cell Disease</u> ," Clinical Immunology and Immunopathology, May 1994, Vol. 71, No. 2, pp. 199-202.	<input type="checkbox"/>	
	ABB	CORVETTA, Angelo, et al.; " <u>Low Number of Complement C3b/C4b Receptors (CR1) on Erythrocytes from Patients with Essential Mixed Cryoglobulinemia, Systemic Lupus Erythematosus and Rheumatoid Arthritis: Relationship with Disease Activity, Anticardiolipin Antibodies, Complement Activation and Therapy</u> ," 1981, J. Rheumatol., Vol. 18, pp. 1021-1025.	<input type="checkbox"/>	
	ACC	COSIO, F.G., et al., " <u>The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients</u> ," Transplantation, October 27, 1996, Vol. 62, No. 8, abstract only.	<input type="checkbox"/>	
	ADD	FREYSDOTTIR, Jona, et al.; " <u>A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes</u> ," 1991, Journal of Immunological Methods, Vol. 142, pp. 45-52.	<input type="checkbox"/>	
	AEE	JOUVIN, Marie-Helene et al.; " <u>Decreased Expression of C3b Receptor (CR1) on Erythrocytes of Patients with Systemic Lupus erythematosus Contrasts with Its Normal Expression in Other Systemic Diseases and Does Not Correlate with the Occurrence or Severity of SLE Nephritis</u> ," Complement; 1986, Vol. 3, pp. 88-96.	<input type="checkbox"/>	
	AFF	LACH-TRIFILIEFF, Estelle, et al., " <u>Complement Receptor 1 (CD35) on Human Reticulocytes: Normal Express in Systemic Lupus Erythematosus and HIV-Infected Patients</u> ," The Journal of Immunology, Vol. 162, No. 12, June 1999, pp. 7549-7554.	<input type="checkbox"/>	
	AGG	LAMPRECHT, P., et al., " <u>Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis</u> ," Annals of the Rheumatic Diseases, April 2001, Vol. 60, pp. 385-390.	<input type="checkbox"/>	
/GG/	AHH	LIANG, Matthew H., et al., " <u>Reliability and Validity of Six Systems for the Clinical Assessment of Disease Activity in Systemic Lupus Erythematosus</u> ," Arthritis Rheum, September 1989, Vol. 32; No. 9; pp. 1107-18.	<input type="checkbox"/>	
Examiner Signature	/Gailene Gabel/ (12/04/2008)		Date Considered	12/04/2008

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/552,,177
				Filing Date	October 5, 2005
				First Named Inventor	Ahearn, Joseph M.
				Art Unit	1641
Examiner Name	Unassigned				
Attorney Docket Number	021182-000410US				
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/GG/	All	MANZI, Susan, et al.; " <u>Measurement of Erythrocyte C4d and Complement Receptor 1 in Systemic Lupus Erythematosus</u> ;" November 2004, Arthritis & Rheumatism, Vol. 50, No. 11, pp. 3596-3604.	<input type="checkbox"/>	
	AJJ	ACCN. No. 85046338 MEDLINE. MCCARTHY, T., et al., " <u>Intrauterine devices and pelvic inflammatory disease</u> ;" Australian and New Zealand Journal of Obstetrics and Gynecology, May 1984, Vol. 24, No. 2, pp. 106-110, Abstract.	<input type="checkbox"/>	
	AKK	MCGEER, P.L. et al.; " <u>Reactions of the Immune System in Chronic Degenerative Neurological Diseases</u> ;" The Canadian Journal of Neurological Sciences; 1991, Vol. 18; pp. 376-379.	<input type="checkbox"/>	
	ALL	ACCN. No. 90367342 MEDLINE. MELICONI, R., et al., " <u>Complement activation products in idiopathic pulmonary fibrosis: relevance of fragment Ba to disease severity</u> ;" Clinical Immunology and Immunopathology, October 1990, Vol. 57, No. 1, pp. 64-73, Abstract.	<input type="checkbox"/>	
	AMM	ROSS, Gordon D. et al.; " <u>Disease-Associated Loss of Erythrocyte Complement Receptors (CR1, C3b Receptors) in Patients with Systemic Lupus Erythematosus and other Diseases Involving Auto antibodies and/or Complement Activation</u> ;" 1985, Journal of Immunology, Vol. 135, No. 3, pp. 2005-2014.	<input type="checkbox"/>	
	ANN	SIROIS, M., et al., " <u>An Enzyme-linked Immunosorbent Assay for the Detection of Complement Components on Red Blood Cells</u> ;" Am. Journ. Clin. Path., July 1984, Vol. 82, No. 1, pp. 67-73.	<input type="checkbox"/>	
	AOO	TAUSK, Francisco, et al., " <u>The Expression of C3b Receptors in the Differentiation of Discoid Lupus Erythematosus and Systemic Lupus Erythematosus</u> ;" Arthritis and Rheumatism, June 1990, Vol. 33, No. 6, pp. 888-892.	<input type="checkbox"/>	
	APP	TILLEY, C.A., et al., " <u>Localisation of Chido and Rodgers Determinants to the C4d Fragment of Human C4</u> ;" Nature; December 14, 1978; Vol. 276; pp. 713-715.	<input type="checkbox"/>	
	AQQ	TSUBOI, Y. et al.; " <u>Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis</u> ;" Neurosurgery and Psychiatry 1994, Vol. 57, pp. 859-861.	<input type="checkbox"/>	
/GG/	ARR	YAMADA, T., et al. " <u>Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d</u> ;" Neuroscience Letters, 1990, Vol. 112, pp. 161-166.	<input type="checkbox"/>	
	ASS		<input type="checkbox"/>	

Examiner Signature	/Gailene Gabel/ (12/04/2008)	Date Considered	12/04/2008
--------------------	------------------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.